Despite promising results on rodent models of obesity and metabolic syndrome showing a reduction in obesity, weight loss and improvement in glucose homeostasis with Β3-AR agonists [85,86], clinical trials testing the same in humans performed poorly, at best [87,88,89]. This evidence concerns the gene AR and obesity disorder.